Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: An Italian pilot study

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue 5, 2002, Pages 477-483

  Barbaro, Giuseppe ^b   Barbarini, Giorgio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic hepatitis C; Consensus interferon; Genotype 1; Hepatitis C virus; Non responders; Relapsers

Indexed keywords

ALPHA2B INTERFERON; CONSENSUS INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; MALE; MENTAL DISEASE; OUTPATIENT; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; LOGISTIC MODELS; MALE; PILOT PROJECTS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

EID: 0036097087     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200205000-00003     Document Type: Article

References (26)

1. Therapy of hepatitis C: A meta-analysis of interferon alpha-2b trials
2. Retreatment of chronic hepatitis C with consensus interferon
3. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
4. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
5. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
6. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: An Italian multicenter experience
7. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
8. Interferon alpha-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon alpha alone: An Italian multicenter, randomized, controlled, clinical study
9. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
10. The role of consensus interferon in chronic hepatitis C infection
11. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
12. Treatment of chronic hepatitis C virus infection with recombinant consensus interferon
13. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection
14. Intramuscular beta interferon for chronic hepatitis C: Is it worth trying?
15. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon
16. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
17. Characterization of the genomic sequence of the type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection
18. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
19. Therapy of hepatitis C: Consensus interferon trials
20. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon
21. Spectrum of virus inhibition by consensus interferon YM643
22. Predictors of response to interferon therapy
23. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C
24. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha-therapy
25. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon